-
Novo Nordisk: Positive progress made in reducing the risk of kidney disease with Smegglutide injections
On March 5th, Danish time, Novo Nordisk announced that its widely used semaglutide injection has made positive progress in treating kidney disease in a double-blind trial called FLOW. Compared with t ... -
Novartis' kidney product portfolio makes its debut at the China International Import Expo, and the company stated that it will actively promote the product's launch
The 7th China International Import Expo (CIIE) is currently being held. The reporter saw at the scene that Novartis' innovative drug combination for the treatment of IgA nephropathy (IgAN), including ...